Trial
NCT03454893
Open Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment-Naive Subjects With Classic Fabry Disease
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
AVROBIO
Collaborators
—
Condition
Fabry Disease
Intervention
AVR-RD-01
Why stopped
AVROBIO has deprioritized its Fabry disease program
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-01-05